Not your average BLOG!

Diabetes: Beyond Metformin Part 2

Part 2 of the SGLT2 inhibitor breakdown. The emerging liver fat evidence. The safety profile of Jardiance, Farxiga, and Invokana. And the single most important medication-coaching conversation in the entire drug series for patients combining these drugs with low-carbohydrate or ketogenic dietary approaches. Part 1 of this SGLT2 conversation covered the underrated cardiovascular and kidney…